Development of a nephrotic syndrome in a patient with gastrointestinal stromal tumor during a long-time treatment with sunitinib

Case Reports in Oncology

Volumn 5, Issue 3, 2012, Pages 651-656

  Pallotti, Maria Caterina ^a   Pantaleo, Maria Abbondanza ^a,b   Nannini, Margherita ^a   Centofanti, Francesca ^a   Fabbrizio, Benedetta ^a   Montanari, Mara ^a   Baraldi, Olga ^a   Saponara, Maristella ^a   Lolli, Cristian ^a   Mandrioli, Anna ^a   Biasco, Guido ^a,b   Prandini, Rita ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Gastrointestinal stromal tumor; Nephrotic syndrome; Proteinuria; Renal toxicity; Sunitinib; Vascular endothelial growth factor

Indexed keywords

CREATININE; IMATINIB; NILOTINIB; PREDNISONE; SUNITINIB;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD PRESSURE REGULATION; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GLOMERULONEPHRITIS; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPOALBUMINEMIA; KIDNEY DYSFUNCTION; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEINURIA; TREATMENT DURATION; TUMOR VOLUME; VESICULAR RASH; WEDGE RESECTION; WEIGHT GAIN;

EID: 84873163214     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000345946     Document Type: Article

References (15)

1. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-3825.
2. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
3. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-1104.
4. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 2012;307:1265-1272.
5. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-1338.
6. Blay JY: Pharmacological management of gastrointestinal stromal tumours: An update on the role of sunitinib. Ann Oncol 2010;21:208-215.
7. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-1968.
8. Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T: Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol 2012;16:310-315.
9. Liu YC, Chang PM, Liu CY, Yang CY, Chen MH, Pan CC, Chen MH: Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma. Jpn J Clin Oncol 2011;41:1277-1281.
10. Turan N, Benekli M, Ozturk SC, Inal S, Memis L, Guz G, Cetin B, Buyukberber S: Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. Ann Pharmacother 2012;46:e27.
11. Kelly RJ, Billemont B, Rixe O: Renal toxicity of targeted therapies. Target Oncol 2009;4:121-133.
12. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC: VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46:439-448.
13. Wu S, Kim C, Baer L, Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21:1381-1389.
14. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, Emile JF, Chabaud S, Pérol D, Blay JY; French Sarcoma Group: Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial. Lancet Oncol 2010;11:942-949.
15. van den Abbeele A, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi R, Demetri G: Imaging kinase target inhibition with SU11248 by FDG-PET in patients (PTS) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). J Clin Oncol 2005;ASCO Annual Meeting Proceedings Vol 23:16S.